SCHEMBL3595896

SCHEMBL3595896

CN(C)C1Cc2ccc(N)cc2NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 1/20 0.47
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
CYP19A1 P11511 1/20 0.34
CRBN Q96SW2 5/20 0.33
HTR5A P47898 3/20 0.33
APAF1 O14727 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TDP2 O95551 1/20 0.31
TRPV1 Q8NER1 2/20 0.30
BRD4 O60885 1/20 0.30
CREBBP Q92793 1/20 0.30
DDB1 Q16531 3/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601169 0.88 CA9 (0.37) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3590237 0.84 CA9 (0.44) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3588367 0.84 CA9 (0.41) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3589697 0.83 CA9 (0.40) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3602382 0.83 TRPV1 (0.45) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3595894 0.82 TRPV1 (0.30) CRBNTRPV1BRD4CREBBPDDB1
SCHEMBL13545487 0.81 CA9 (0.39) CA9MEN1KMT2AKDM4EGAA
SCHEMBL3598181 0.81 TRPV1 (0.47) CA9MEN1KMT2AKDM4EGAA
SCHEMBL1709931 0.80 CA9 (0.51) CA9MEN1KMT2AKDM4EGAA
SCHEMBL13545280 0.79 TRPV1 (0.36) MEN1KMT2AMAPTCRBNTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CA9 1531/4885MEN1 2424/4885KMT2A 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.